AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 7988622 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 400 mg
Number of subjects: 6
Study 7988622 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol 80 mg
Number of subjects: 6
Study 7988622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 6
Study 2471287 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose aprotinin (about 840 mg, equivalent to 6 million Kallikrein inactivator units)
Number of subjects: 80
Study 2471287 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (no aprotinin)
Number of subjects: 80
Study 1103273 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbenoxolone 100 mg three times daily
Number of subjects: 57
Study 1103273 — intervention group
Group type: COMPARATOR
Intervention: Geranyl farnesyl acetate (Gefarnate) 100 mg three times daily
Number of subjects: 57
Study 31192869 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative anticoagulation (IV heparin or heparin with dextran)
Number of subjects: 282
Study 31192869 — intervention group
Group type: COMPARATOR
Intervention: No postoperative anticoagulation
Number of subjects: 282
Study 28167330 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple P Online Brief (n=100)
Number of subjects: 200
Study 28167330 — intervention group
Group type: COMPARATOR
Intervention: Waitlist Control (n=100)
Number of subjects: 200
Study 26195265 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitor sitagliptin
Number of subjects: 55
Study 26195265 — intervention group
Group type: COMPARATOR
Intervention: Sulfonylurea (SU)
Number of subjects: 55
Study 22929209 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial provider (Weight Watchers)
Number of subjects: 772
Study 22929209 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 772
Study 21348806 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.2 mg + glimepiride
Number of subjects: 0
Study 21348806 — intervention group
Group type: EXPERIMENTAL
Intervention: liraglutide 1.8 mg + glimepiride
Number of subjects: 0
Study 21348806 — intervention group
Group type: COMPARATOR
Intervention: rosiglitazone 4 mg + glimepiride
Number of subjects: 0
Study 18959634 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 601
Study 18959634 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 601
Study 16485321 — intervention group
Group type: EXPERIMENTAL
Intervention: Postictal scan in patients
Number of subjects: 10
Study 16485321 — intervention group
Group type: EXPERIMENTAL
Intervention: Interictal scan in patients
Number of subjects: 10
Study 16485321 — intervention group
Group type: COMPARATOR
Intervention: Control group scans
Number of subjects: 10
Study 16485321 — intervention group
Group type: EXPERIMENTAL
Intervention: Inter-group comparison
Number of subjects: 10
Study 14614218 — intervention group
Group type: EXPERIMENTAL
Intervention: Isoflavone extract (61.8 mg) for three months
Number of subjects: 22
Study 14614218 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 22
Study 10901342 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextroamphetamine
Number of subjects: 23
Study 10901342 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 8750523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (R) 2000 rads in 5 days
Number of subjects: 703
Study 8750523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation plus prednisone (R + P) 7.5 mg daily for up to five years
Number of subjects: 703
Study 8750523 — intervention group
Group type: COMPARATOR
Intervention: No further therapy (NT)
Number of subjects: 703
Study 8750523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation (R)
Number of subjects: 703
Study 8750523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation plus prednisone (R + P)
Number of subjects: 703
Study 8750523 — intervention group
Group type: EXPERIMENTAL
Intervention: Ovarian irradiation with or without prednisone therapy
Number of subjects: 703
Study 1421933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gentamicin (10 mg/kg body weight/day for five days)
Number of subjects: 92
Study 1421933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 1421933 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral gentamicin and placebo
Number of subjects: 92
Study 4082295 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP)
Number of subjects: 82
Study 4082295 — intervention group
Group type: COMPARATOR
Intervention: Alizapride (ALZ)
Number of subjects: 82
Study 4082295 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (MCP) in cisplatin-treated patients
Number of subjects: 82
Study 4082295 — intervention group
Group type: COMPARATOR
Intervention: Alizapride (ALZ) in cisplatin-treated patients
Number of subjects: 82
Study 29309883 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of 4.0-5.0 cm
Number of subjects: 100
Study 29309883 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of 4.5-5.5 cm
Number of subjects: 100
Study 29309883 — intervention group
Group type: EXPERIMENTAL
Intervention: Target depth of 5.0-6.0 cm
Number of subjects: 100
Study 29309883 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall performance
Number of subjects: 100
Study 27377549 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication Review Tool
Number of subjects: 60
Study 27377549 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 60
Study 24353124 — intervention group
Group type: EXPERIMENTAL
Intervention: CO2 insufflation
Number of subjects: 107
Study 24353124 — intervention group
Group type: COMPARATOR
Intervention: Air insufflation
Number of subjects: 107
Study 22371092 — intervention group
Group type: EXPERIMENTAL
Intervention: Drag suit training
Number of subjects: 18
Study 22371092 — intervention group
Group type: COMPARATOR
Intervention: Control group (typical training attire)
Number of subjects: 18
Study 21265353 — intervention group
Group type: EXPERIMENTAL
Intervention: Restricted fluid resuscitation (no induction bolus, then LR 2 mL/kg/h)
Number of subjects: 27
Study 21265353 — intervention group
Group type: COMPARATOR
Intervention: Standard fluid resuscitation (500 LR induction bolus, then LR 7 mL/kg/h x 1 h, then 5 mL/kg/h)
Number of subjects: 27
Study 18504252 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard radiosensitised induction chemoradiotherapy (arm A) with cisplatin (90 mg/m(2) day 1) plus etoposide
Number of subjects: 204
Study 18504252 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily radiosensitised induction chemoradiotherapy (arm B) with cisplatin (6 mg/m(2)/day) plus etoposide
Number of subjects: 204
Study 18504252 — intervention group
Group type: COMPARATOR
Intervention: Standard radiosensitised induction chemoradiotherapy (arm A)
Number of subjects: 204
Study 18504252 — intervention group
Group type: COMPARATOR
Intervention: Daily radiosensitised induction chemoradiotherapy (arm B)
Number of subjects: 204
Study 15591305 — intervention group
Group type: EXPERIMENTAL
Intervention: n-3 substituted diet (N3)
Number of subjects: 0
Study 15591305 — intervention group
Group type: COMPARATOR
Intervention: Regular high-fat diet (HF)
Number of subjects: 0
Study 12942708 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Number of subjects: 138
Study 12942708 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin + clavulanic acid
Number of subjects: 138
Study 12942708 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antibiotics)
Number of subjects: 138
Study 11074201 — intervention group
Group type: EXPERIMENTAL
Intervention: Single‐balloon expandable tubular stent
Number of subjects: 32
Study 8796462 — intervention group
Group type: EXPERIMENTAL
Intervention: Family scenario
Number of subjects: 187
Study 8796462 — intervention group
Group type: EXPERIMENTAL
Intervention: Context-free list
Number of subjects: 187
Study 8796462 — intervention group
Group type: EXPERIMENTAL
Intervention: Cultural context
Number of subjects: 187
Study 8796462 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrative data
Number of subjects: 187
Study 1536352 — intervention group
Group type: EXPERIMENTAL
Intervention: AIDS risk reduction intervention
Number of subjects: 157
Study 1536352 — intervention group
Group type: COMPARATOR
Intervention: Control intervention on career opportunities
Number of subjects: 157
Study 6365409 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin II infusion alone
Number of subjects: 25
Study 6365409 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin II infusion with prostaglandin E2
Number of subjects: 25
Study 6365409 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 administration alone
Number of subjects: 25
Study 31671873 — intervention group
Group type: EXPERIMENTAL
Intervention: Aromatherapy combined with music therapy
Number of subjects: 98
Study 28602779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg per day fasted
Number of subjects: 231
Study 28602779 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Number of subjects: 231
Study 28602779 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib
Number of subjects: 231
Study 28602779 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 231
Study 25989338 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab 200 mg
Number of subjects: 246
Study 25989338 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab 400 mg
Number of subjects: 246
Study 25989338 — intervention group
Group type: EXPERIMENTAL
Intervention: Briakinumab 700 mg
Number of subjects: 246
Study 25989338 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 246
Study 24099474 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg twice daily
Number of subjects: 40
Study 24099474 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 20 mg twice daily
Number of subjects: 40
Study 24099474 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole 30 mg twice daily
Number of subjects: 40
Study 24099474 — intervention group
Group type: COMPARATOR
Intervention: Rabeprazole 10 mg twice daily
Number of subjects: 40
Study 21417971 — intervention group
Group type: EXPERIMENTAL
Intervention: Formaldehyde treatment of temporalis muscle fascia grafts
Number of subjects: 54
Study 21417971 — intervention group
Group type: COMPARATOR
Intervention: Control group (no formaldehyde treatment)
Number of subjects: 54
Study 19113796 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective serotonin reuptake inhibitors (SSRIs) such as paroxetine and sertraline, mirtazapine, and nefazodone as pharmacologic therapy for depression in heart failure patients.
Number of subjects: 0
Study 19113796 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-blockers in patients with depression and heart failure.
Number of subjects: 0
Study 17000930 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosinopril 20 mg
Number of subjects: 384
Study 17000930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 384
Study 15849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia pneumoniae positive (7/51 children with asthma)
Number of subjects: 51
Study 15849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlamydia trachomatis positive (2/51 patients with asthma)
Number of subjects: 51
Study 15849399 — intervention group
Group type: EXPERIMENTAL
Intervention: Infected children with chlamydial IgA
Number of subjects: 51
Study 11574184 — intervention group
Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens (CEE) 0.625 mg alone for 30 days
Number of subjects: 18
Study 11574184 — intervention group
Group type: EXPERIMENTAL
Intervention: CEE + continuous combined medroxyprogesterone acetate (MPA) 2.5 mg/daily for 28 days
Number of subjects: 18
Study 11574184 — intervention group
Group type: COMPARATOR
Intervention: CEE + cyclical MPA (10 mg o.d. from day 16 to day 28)
Number of subjects: 18
Study 9625845 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (TX) 175 mg/m2 by 3 h i.v. infusion every 21 days
Number of subjects: 70
Study 9625845 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (TX)
Number of subjects: 70
Study 8160217 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical therapy and carotid endarterectomy
Number of subjects: 444
Study 8160217 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy alone
Number of subjects: 444
Study 3116132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN) for 9.7 +/- 1.1 days
Number of subjects: 92
Study 3116132 — intervention group
Group type: EXPERIMENTAL
Intervention: Total parenteral nutrition (TPN)
Number of subjects: 92
Study 3116132 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 92
Study 30201128 — intervention group
Group type: EXPERIMENTAL
Intervention: Wavefront-guided laser in situ keratomileusis (LASIK)
Number of subjects: 34
Study 30201128 — intervention group
Group type: COMPARATOR
Intervention: Wavefront-guided photorefractive keratectomy (PRK)
Number of subjects: 34
Study 26599376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin intake at 8.00 AM
Number of subjects: 0
Study 26599376 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin intake at 8.00 PM
Number of subjects: 0
Study 25611785 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment in the GLUCOLD trial
Number of subjects: 89
Study 25611785 — intervention group
Group type: COMPARATOR
Intervention: Asthma-associated gene signatures in COPD
Number of subjects: 89
Study 23820669 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate intensity aerobic exercise (GT)
Number of subjects: 22
Study 23820669 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 22
Study 22071933 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity pulsed ultrasound (LIPUS)
Number of subjects: 36
Study 22071933 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LIPUS)
Number of subjects: 36
Study 19238075 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoledronic acid and interleukin-2
Number of subjects: 0
Study 19238075 — intervention group
Group type: COMPARATOR
Intervention: Zoledronic acid alone
Number of subjects: 0
Study 16403243 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined cognitive behavioral therapy (CBT) and pharmacotherapy intervention
Number of subjects: 232
Study 16403243 — intervention group
Group type: COMPARATOR
Intervention: Usual primary-care treatment
Number of subjects: 232
Study 12602908 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT 50 mg/m2 bimonthly schedule
Number of subjects: 3
Study 12602908 — intervention group
Group type: COMPARATOR
Intervention: DCT 75 mg/m2 every 3 weeks (calibration arm)
Number of subjects: 3
Study 12602908 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT 60 mg/m2 bimonthly schedule
Number of subjects: 3
Study 12602908 — intervention group
Group type: EXPERIMENTAL
Intervention: DCT 40 mg/m2 bimonthly schedule
Number of subjects: 3
Study 12602908 — intervention group
Group type: COMPARATOR
Intervention: DCT 75 mg/m2 every 3 weeks
Number of subjects: 3
Study 10885599 — intervention group
Group type: EXPERIMENTAL
Intervention: FEC/EM + LND
Number of subjects: 326
Study 10885599 — intervention group
Group type: COMPARATOR
Intervention: FEC/EM
Number of subjects: 326
Study 10885599 — intervention group
Group type: EXPERIMENTAL
Intervention: EM+/‐LND
Number of subjects: 326
Study 10885599 — intervention group
Group type: COMPARATOR
Intervention: FEC+/‐LND
Number of subjects: 326
Study 10885599 — intervention group
Group type: EXPERIMENTAL
Intervention: LND arms
Number of subjects: 326
Study 9100679 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic antibiotics (three perioperative doses of cefazolin)
Number of subjects: 250
Study 9100679 — intervention group
Group type: COMPARATOR
Intervention: No prophylaxis (NONE group)
Number of subjects: 250
Study 8350342 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation Condition (subjects told their performance was being evaluated and videotaped)
Number of subjects: 0
Study 8350342 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonevaluation Condition (subjects told their performance was not being observed)
Number of subjects: 0
Study 8350342 — intervention group
Group type: COMPARATOR
Intervention: Task performance
Number of subjects: 0
Study 3646271 — intervention group
Group type: EXPERIMENTAL
Intervention: Individually planned consecutive teaching sessions
Number of subjects: 0
Study 3646271 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 0
Study 31679753 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatments for depression
Number of subjects: 465
Study 29248995 — intervention group
Group type: EXPERIMENTAL
Intervention: 5L-SP approach
Number of subjects: 1399
Study 29248995 — intervention group
Group type: COMPARATOR
Intervention: Crosswalk
Number of subjects: 1399
Study 29248995 — intervention group
Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 1399
Study 27273710 — intervention group
Group type: EXPERIMENTAL
Intervention: SFC50 (salmeterol xinafoate 50 μg/day and fluticasone propionate 100 μg/day)
Number of subjects: 35
Study 24548866 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin)
Number of subjects: 0
Study 24548866 — intervention group
Group type: COMPARATOR
Intervention: XELOX (capecitabine+oxaliplatin)
Number of subjects: 0
Study 24548866 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin) with pump malfunction
Number of subjects: 0
Study 24548866 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX‐4 (5‐fluorouracil (5‐FU)+oxaliplatin) without pump malfunction
Number of subjects: 0
Study 24548866 — intervention group
Group type: EXPERIMENTAL
Intervention: Pump malfunctions
Number of subjects: 0
Study 24548866 — intervention group
Group type: EXPERIMENTAL
Intervention: Efficacy outcomes
Number of subjects: 0
Study 22987918 — intervention group
Group type: EXPERIMENTAL
Intervention: Low Na(+) diet (10 mmol/d)
Number of subjects: 185
Study 22987918 — intervention group
Group type: COMPARATOR
Intervention: High Na(+) diet (300 mmol/d)
Number of subjects: 185
Study 22987918 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in SLC4A5 (rs7571842 and rs10177833)
Number of subjects: 185
Study 22987918 — intervention group
Group type: EXPERIMENTAL
Intervention: SNPs in GRK4
Number of subjects: 185
Study 22987918 — intervention group
Group type: EXPERIMENTAL
Intervention: SLC4A5 SNPs after adjustment for BMI and age
Number of subjects: 185
Study 22987918 — intervention group
Group type: EXPERIMENTAL
Intervention: Meta-analysis of SNPs rs7571842 and rs1017783
Number of subjects: 185
Study 20566010 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg tamsulosin oral tablets once daily (GB)
Number of subjects: 150
Study 20566010 — intervention group
Group type: COMPARATOR
Intervention: Placebo (GA)
Number of subjects: 150
Study 18949104 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic exercise training (AET) combined with irbesartan
Number of subjects: 21
Study 18949104 — intervention group
Group type: COMPARATOR
Intervention: Aerobic exercise training (AET) with placebo
Number of subjects: 21
Study 16481664 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate transdermal system (MTS) 10, 16, 20, and 27 mg applied in the morning for 9 hours
Number of subjects: 80
Study 16481664 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12540224 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib (50 mg)
Number of subjects: 45
Study 12540224 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibuprofen (600 mg)
Number of subjects: 45
Study 12540224 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 12540224 — intervention group
Group type: EXPERIMENTAL
Intervention: Periapical diagnosis of acute apical periodontitis
Number of subjects: 45
Study 10849524 — intervention group
Group type: EXPERIMENTAL
Intervention: PBPC (Peripheral Blood Progenitor Cells)
Number of subjects: 61
Study 10849524 — intervention group
Group type: COMPARATOR
Intervention: BM (Bone Marrow)
Number of subjects: 61
Study 9095512 — intervention group
Group type: EXPERIMENTAL
Intervention: Monoclonal antibodies in 'Other Blood Groups'
Number of subjects: 0
Study 9095512 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard red cell serological techniques
Number of subjects: 0
Study 8250363 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg midazolam orally and 0.2 mg sublingual buprenorphine (group 2)
Number of subjects: 287
Study 8250363 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg midazolam orally and 0.4 mg sublingual buprenorphine (group 3)
Number of subjects: 287
Study 8250363 — intervention group
Group type: COMPARATOR
Intervention: 5 mg midazolam orally (group 1)
Number of subjects: 287
Study 3879105 — intervention group
Group type: EXPERIMENTAL
Intervention: 24R,25 (OH)2D3 (10 micrograms daily)
Number of subjects: 40
Study 3879105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 31074641 — intervention group
Group type: EXPERIMENTAL
Intervention: Etirinotecan pegol
Number of subjects: 0
Study 31074641 — intervention group
Group type: COMPARATOR
Intervention: Treatment of physician's choice (control)
Number of subjects: 0
Study 28724547 — intervention group
Group type: EXPERIMENTAL
Intervention: Aliskiren (6 months)
Number of subjects: 21
Study 28724547 — intervention group
Group type: COMPARATOR
Intervention: Hydrochlorothiazide (6 months)
Number of subjects: 21
Study 25538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 300 mg monotherapy (V)
Number of subjects: 173
Study 25538178 — intervention group
Group type: EXPERIMENTAL
Intervention: Vandetanib 100 mg plus gemcitabine (V/G)
Number of subjects: 173
Study 25538178 — intervention group
Group type: COMPARATOR
Intervention: Gemcitabine plus placebo (G/P)
Number of subjects: 173
Study 23161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 16.2 mg
Number of subjects: 10
Study 23161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine 32.4 mg
Number of subjects: 10
Study 23161001 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 23161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 1 mg
Number of subjects: 10
Study 23161001 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydromorphone 2 mg
Number of subjects: 10